Because our analyses of tumor-bearing mice treated with cGAMP also revealed an increased frequency of IL-9-producing CD4 T cells in the tumor microenvironment (online supplemental figure S2G, H), we finally evaluated the contribution of other CD4 T cell-derived cytokines (IL-9, IL-17, and IL-4) to the anticancer effects of cGAMP. This evidence concerns the gene IL17A and neoplasm.